In­ter­cep­t's NASH drug is again re­ject­ed by FDA, lead­ing the com­pa­ny to re­struc­ture in piv­ot from dis­ease

In­ter­cept Phar­ma­ceu­ti­cals’ NASH drug obeti­cholic acid was re­ject­ed by the FDA for a sec­ond time on Thurs­day, and the com­pa­ny says it will now dis­con­tin­ue “all NASH-re­lat­ed in­vest­ment,” piv­ot its fo­cus to rare and se­ri­ous liv­er dis­eases, and lay off about one-third of its work­force.

A re­sub­mis­sion would re­quire, at a min­i­mum, com­plete da­ta from the long-term out­comes phase of its piv­otal RE­GEN­ER­ATE study, In­ter­cept said it was told by the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER